Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients

G. C. Yee, M. S. Kennedy, R. Storb, E. D. Thomas

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

The effect of hepatic dysfunction, defined as abnormal serum bilirubin level, on oral cyclosporine (CSP) pharmacokinetics was examined in 28 marrow transplant patients who received CSP for prophylaxis of graft-v-host disease. Serum CSP concentrations were measured by radioimmunoassay. Forty-one concentration-time courses were studied, divided among patients with no (<1.2 mg/dL), mild (1.2 to 2.0 mg/dL), and moderate (2.0 to 5.0 mg/dL) hepatic dysfunction. CSP elimination, as determined by elimination rate constant and clearance, was delayed in patients with moderate hepatic dysfunction compared to those with no hepatic dysfunction (P <.05). The volume of distribution, lag time for absorption, maximum serum concentration, and time at which the maximum concentration was achieved was not affected by hepatic function. These data indicate that patients with moderate hepatic dysfunction have delayed CSP or CSP metabolite elimination and may be at higher risk for developing CSP-related toxicity.

Original languageEnglish (US)
Pages (from-to)1277-1279
Number of pages3
JournalBlood
Volume64
Issue number6
DOIs
StatePublished - 1984

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Effect of hepatic dysfunction on oral cyclosporine pharmacokinetics in marrow transplant patients'. Together they form a unique fingerprint.

  • Cite this